Medical and Pharmaceutical Krystal Biotech co-founder makes Forbes 250 innovators list News comes after the company attained RMAT designation from the FDA for its lung cancer drug Rowan Dunne4 days ago
Medical and Pharmaceutical Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test The ctDNA blood draw is known for its ultrasensitive detection capabilities Rowan Dunne5 days ago
Psychedelics Enveric Biosciences skyrockets on patent allowance for psychedelic-inspired molecules Lead drug candidate EB-301 is structurally similar to DMT Rowan DunneDecember 11, 2025
AI and Autonomy Eli Lilly launches AI-powered drug development platform for biotech operators 'TuneLab' allows biotech companies to securely use Eli Lilly's AI models to gain insights about their IP Rowan DunneSeptember 10, 2025
Medical and Pharmaceutical Lantern Pharma completes Japanese enrolment for lung cancer drug trial Japan has an extremely high rate of non-smokers getting diagnosed with the disease Rowan DunneAugust 5, 2025
Medical and Pharmaceutical bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test It will be issued within 3 months provided that there are no opposition filings made by third parties Rowan DunneJanuary 22, 2025
Science and Research IGM Biosciences slides by 66% on discontinued drug development and lay offs The biotech company has put the halt on 2 therapeutics used to treat arthritis, lupus and myasthenia gravis Rowan DunneJanuary 10, 2025
Medical and Pharmaceutical Roche secures rights to Chinese biotech company’s small cell lung cancer drug Innovent Biologics will receive up to US$1 billion in milestone payments and royalties Rowan DunneJanuary 3, 2025
Medical and Pharmaceutical Portage Biotech soars after initiating proceedings for iOx Therapeutics sale The stock went up by over 185% after the LOI was announced Rowan DunneDecember 17, 2024
Medical and Pharmaceutical MIRA Pharma up 27% on ketamine analogue’s preclinical results for chemotherapy pain This pharmaceutical company is also developing a synthetic cannabinoid drug to treat anxiety and cognitive decline Rowan DunneOctober 30, 2024